|
Meca-Lallana JE, Prieto Gonzalez JM, Caminero Rodriguez AB, Olascoaga Urtaza J, Alonso AM, Duran Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Perez Ruiz D, Calles C, Hernandez MA, Hervas Garcia M, Mendoza Rodriguez A, Berdei Montero Y, Tellez N, Herrera Varo N, Sotoca J, Presas-Rodriguez S, Querol Gutierrez LA, Hervas Pujol M, Batlle Nadal J, Martin Ozaeta G, Gubieras Lillo L, Martinez Yelamos S, Ramio-Torrenta L, Mallada Frechin J, Belenguer Benavides A, Gascon-Gimenez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gomez Gutierrez M, Duran C, Rodriguez Regal A, Alvarez E, Garcia-Estevez DA, Lopez Real AM, Llaneza Gonzalez MA, Marzo Sola ME, Sanchez-Menoyo JL, Oterino A, Villaverde Gonzalez R, Castillo-Trivino T, Alvarez de Arcaya A, Llarena C. Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. PubMed PMID: 37861931; PubMed Central PMCID: PMC10630277.
AÑO: 2023; IF: 3.9
|
37861931
|
Saiz A, Mora S, Blanco J; en representacion de los investigadores del estudio COMPLIANCE. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study. Neurologia. 2015 May;30(4):214-22. doi: 10.1016/j.nrl.2013.12.008. Epub 2014 Jan 28. English, Spanish. PubMed PMID: 24484756.
AÑO: 2015; IF: 3.9
|
|
Fernandez-Velasco JI, Monreal E, Kuhle J, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Oreja-Guevara C, Gascon-Gimenez F, Sainz de la Maza S, Walo-Delgado PE, Lapuente-Suanzes P, Maceski A, Rodriguez-Martin E, Roldan E, Villarrubia N, Saiz A, Blanco Y, Diaz-Perez C, Valero-Lopez G, Diaz-Diaz J, Aladro Y, Brieva L, Iniguez C, Gonzalez-Suarez I, Rodriguez de Antonio LA, Garcia-Dominguez JM, Sabin J, Llufriu S, Masjuan J, Costa-Frossard L, Villar LM. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Front Immunol. 2022 Mar 21;13:842354. doi: 10.3389/fimmu.2022.842354. eCollection 2022. PubMed PMID: 35386690; PubMed Central PMCID: PMC8977599.
AÑO: 2022; IF: 7.3
|
|
Valero-Lopez G, Millan-Pascual J, Iniesta-Martinez F, Delgado-Marin JL, Jimenez-Veiga J, Tejero-Martin AB, Leon-Hernandez A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE. Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30). Mult Scler Relat Disord. 2022 Oct;66:104038. doi: 10.1016/j.msard.2022.104038. Epub 2022 Jul 7. PubMed PMID: 35870370.
AÑO: 2022; IF: 4.0
|